Skip to main content
SpringerLink
Log in

Systemic antifungal agents

  • Symposium on Antimicrobials—I
  • Published:
The Indian Journal of Pediatrics Aims and scope Submit manuscript

Abstract

Anti-fungal agents are classified under two major headings, systematic and topical agents. Only systematic anti-fungal agents will be discussed in this chapter. Since the discovery in 1955, amphotericin B has been the cornerstone of anti-fungal treatment. It is active against most species of fungl. However,Candida lusitaniae, Pseudallescheria boydii, and fusarium spp have primary resistance to amphotericin B. Recently, new liposomal preparations of amphotericin B have been developed. They are less nephrotoxic. The azole family of anti-fungal includes two broad classes: the imidazoles (clotrimazote, ketoconazote, miconazole) and the triazoles (flucouazole and itracouazole). Imidazoles are still widely used for the treatment of superficial mycoses and vaginal candidiasis. The systematic triazoles are more slowly metabolized and have less effect on human synthesis than imidazoles, hence they are preferred for systemic therapy. Flucytosine is a fluorinated pyrimidine. Clinically, the principal use of flucytosine is as adjunctive therapy with amphotericin B in the treatment of candidial or cryptococcal diseases. Griseofuluin is derived from penicillium. It is fungistaticin vitro for species of dermatophytes. It is useful for the treatment of tinea capitis and tinea unginum.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Stamos JK, Rowley AH. Candidemia in a Pediatric Population.Clin Infect Dis 1995; 20: 571–575.

    PubMed  CAS  Google Scholar 

  2. Gold W, Stout NA, Pagano JF, Donovick R. Amphotericin A and B, Antifungal antibiotics produced by a streptomyces.In Vitro Studies.Antibiot Ann 1955–1956; 3: 579–586.

    Google Scholar 

  3. Gallis H, Drew R, Pickard W. Amphotericin B: 30 Years of Clinical Experience.Rev Infect Dis 1990; 12: 308–329.

    PubMed  CAS  Google Scholar 

  4. Oldfield EC, Garst PD, Hostettler Cet al. Randomized, Double-blinded Trial of 1-versus-4 hour Amphotericin B Infusion Duration.Antimicrobial Agnets Chemother 1990; 34: 1402.

    Google Scholar 

  5. Gale EF. Nature and Development of Phenotypic Resistance to Amphotericin B in Candida Albicans.Adv Microb Physiol 1986; 27: 277–319.

    PubMed  CAS  Google Scholar 

  6. DeMuri GP, Hostetter MK. Resistance to Antifungal Agents.Ped Clin of North America 1995; 42: 665–685.

    CAS  Google Scholar 

  7. Sugar AM. Use of Amphotericin B with Azole Antifungal Drugs: What Are We Doing?Antimicrob Agents Chemother 1995; 39: 1907.

    PubMed  CAS  Google Scholar 

  8. Wright DG, Robichavd J, Pizzo PA, Deisseroth AB. Lethal Pulmonary Reactions Associated with the Combined Use of Amphotericin B and Leukocyte Transfusions.N Engl J Med 1981; 304: 1185.

    Article  PubMed  CAS  Google Scholar 

  9. Llanos A, Ciezo, Bernado Jet al. Effect of Salt Supplementation on Emphotericin B Nephrotoxicity.Kidney Int 1991; 40: 302.

    Article  PubMed  CAS  Google Scholar 

  10. Bennet JE. Antifungal Angets In Gilman AG, Rall TW, Nics AS, Taylor P, eds.The Pharmacological of Therapeutics. Maxwell, Macmillan Publishing Co. 1991; 1065–1073.

  11. Como JA, Dismukes WE. Drug Therapy: Oral Azole Drugs as Systemic Antifungal Therapy.N Engl J Med 1994; 330: 263–272.

    Article  PubMed  CAS  Google Scholar 

  12. Saag MS, Dismukes WE. Azole Antifungal Agents: Emphasis on New Triazoles.Antimicrob Agents Chemother 1988; 32: 1–8.

    PubMed  CAS  Google Scholar 

  13. Schmirt HJ, Edwards F, Andrade J, Niki Y, Armstrong D. Comparison of Azoles Against Aspergilliin vitro and in Experimental Model of Pulmonary Aspergillosis.Chemotherapy 1992; 38: 118–26.

    Article  Google Scholar 

  14. Pfaller MA, Rinaldi MG. Antifungal Susceptibility Testing. Current State of Technology, Limitations and Standardization.Infect Dis Clin North Am 1993; 7: 435–444.

    PubMed  CAS  Google Scholar 

  15. Lewis JH, Zimmerman HJ, Benson GD, Ishak KG. Hepatic Injury Associated with Ketoconazole Therapy: Analysis of 33 Cases.Gastroenterology 1984; 86: 503–513.

    PubMed  CAS  Google Scholar 

  16. Crane JK, Shih HT. Syncope and Cardiac Arrhythmias Due to Interaction Between Itraconazole and Terfenadine.Am J Med 1993; 95: 445–446.

    Article  PubMed  CAS  Google Scholar 

  17. Dismukes WE. Azole Anti-fungal Drugs: Old and New.Annals of Intern Medicine 1988; 109: 177–179.

    CAS  Google Scholar 

  18. Tucker RM, Williams PL, Arathoon EGet al. Pharmacokinetics of Fluconazole in Cerebrospinal Fluid and Serum in Human Coccidioidal Meningitis.Antimicrob Agents Chemother 1988; 32: 369–373.

    PubMed  CAS  Google Scholar 

  19. Lazar JD, Wilner KD. Drug Interactions with Fluconazole.Rev Infect Dis 1990; 12 (suppl 3): 5 327–333.

    Google Scholar 

  20. Agrawal PB, Narang A, and Kumar P. Fluconazole.Indian J Pediatr 1996; 63: 775–780.

    Article  PubMed  CAS  Google Scholar 

  21. Bozzett SA, Larsen RA, Chiv Jet al. A Placebocontrolled Trial of Maintenance Therapy with Fluconazole After Treatment of Cryptococcal Meningitis in the Acquired Immunodeficiency Syndrome.N Engl J Med 1991; 324: 580–584.

    Article  Google Scholar 

  22. Hetherington SV. Orlicek S. Patric C. Antifungal Agents. In Long SS, Pickering LK, Prober CG, eds.Principles and Practice of Pediatric Infectious Diseases. New York, Churchill Livingstone, 1997.

    Google Scholar 

  23. Barone JA, Koh JG, Bierman RHet al. Food Interaction and Steady State Pharmacokinetics of Itraconazole Capsules in Healthy Male Volunteers.Antimicrob Agents Chemother 1993; 37: 778–784.

    PubMed  CAS  Google Scholar 

  24. Sachs MK, Blanchard LM, Green PJ. Interaction of Itraconazole and Digoxin.Clin Infect Dis 1993; 16: 400–403.

    PubMed  CAS  Google Scholar 

  25. Bikers DR. Antifungal Therapy: Potential Interactions with Other Classes of Drugs.J Am Acad Dermatol 1994; 31: 587–590.

    Google Scholar 

  26. Svarezs. New Antifungal Therapy for Children.Advances in Dermatology 1997; 12: 195–209.

    Google Scholar 

  27. Terrell C. Antifungal Agents, Part II, The Azoles.Mayo Clinic Proc 1999; 74: 78–100.

    CAS  Google Scholar 

  28. Polak A, Scholer HJ. Mode of Action of 5-Fluorocytosine and Mechanisms of Resistance.Chemotherapy 1975; 21: 113.

    Article  PubMed  CAS  Google Scholar 

  29. Speller D, Davies M. Sensitivity of Yeasts to 5-Fluorocytosis.J Med Microbiol 1973; 6: 315–321.

    PubMed  CAS  Google Scholar 

  30. Francis P, Walsh T. Evolving Role of Flucytosine in Immunocompromised Patients: New Insights into Safety, Pharmacokinetics and Antifungal Therapy.Clin Infect Dis 1992; 15: 1003–1018.

    PubMed  CAS  Google Scholar 

  31. Tanz RR, Hebert AA, Esterly NB. Treating Tinea Capitis: Should Ketoconazole Replace Griseofulvin?J Pediatr 1988; 112: 987–991.

    Article  PubMed  CAS  Google Scholar 

  32. Frieden L, Howard R. Tinea Capitis: Epidemiology, Diagnosis, Treatment and Control.J Am Acad Dermatol 1994; 31: 542–546.

    Google Scholar 

  33. Macro F. p faller MA, Messerset al.In vitro activities of voriconazole (UK-109, 496) and four other antifungal agents against 394 clinical isolates of canidida spp.Antimicrobial Agents Chemotherapy 1998; 42: 3242–3244.

    Google Scholar 

  34. Georgopadakon NH. Antifungals: mechanism of action and resistance, established and novel drugs.Gurr Opin Microbial 1998; 1: 547–557.

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Pediatrics, Hurley Medical Centre, Michigan State University-College of Human Medicine, One Hurley Plaza, 48503, Flint, Michigan

    Walid Abuhammour

  2. Department of Medicine, Hurley Medical Centre, Michigan State University-College of Human Medicine, One Hurley Plaza, 48503, Flint, Michigan

    Eyassu Habte-Gabr

Authors
  1. Walid Abuhammour
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Eyassu Habte-Gabr
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Walid Abuhammour.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Abuhammour, W., Habte-Gabr, E. Systemic antifungal agents. Indian J Pediatr 68, 655–668 (2001). https://doi.org/10.1007/BF02752281

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF02752281

Key words

Search

Navigation